497 related articles for article (PubMed ID: 31385441)
1. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
Charles-Schoeman C; DeMasi R; Valdez H; Soma K; Hwang LJ; Boy MG; Biswas P; McInnes IB
Arthritis Rheumatol; 2019 Sep; 71(9):1450-1459. PubMed ID: 31385441
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Charles-Schoeman C; Wicker P; Gonzalez-Gay MA; Boy M; Zuckerman A; Soma K; Geier J; Kwok K; Riese R
Semin Arthritis Rheum; 2016 Dec; 46(3):261-271. PubMed ID: 27443588
[TBL] [Abstract][Full Text] [Related]
3. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
Gladman DD; Charles-Schoeman C; McInnes IB; Veale DJ; Thiers B; Nurmohamed M; Graham D; Wang C; Jones T; Wolk R; DeMasi R
Arthritis Care Res (Hoboken); 2019 Oct; 71(10):1387-1395. PubMed ID: 31112005
[TBL] [Abstract][Full Text] [Related]
4. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.
Sands BE; Colombel JF; Ha C; Farnier M; Armuzzi A; Quirk D; Friedman GS; Kwok K; Salese L; Su C; Taub PR
Inflamm Bowel Dis; 2021 May; 27(6):797-808. PubMed ID: 32870265
[TBL] [Abstract][Full Text] [Related]
5. Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis.
Wu JJ; Strober BE; Hansen PR; Ahlehoff O; Egeberg A; Qureshi AA; Robertson D; Valdez H; Tan H; Wolk R
J Am Acad Dermatol; 2016 Nov; 75(5):897-905. PubMed ID: 27498960
[TBL] [Abstract][Full Text] [Related]
6. Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.
Liao KP; Liu J; Lu B; Solomon DH; Kim SC
Arthritis Rheumatol; 2015 May; 67(8):2004-10. PubMed ID: 25917955
[TBL] [Abstract][Full Text] [Related]
7. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.
Charles-Schoeman C; Fleischmann R; Davignon J; Schwartz H; Turner SM; Beysen C; Milad M; Hellerstein MK; Luo Z; Kaplan IV; Riese R; Zuckerman A; McInnes IB
Arthritis Rheumatol; 2015 Mar; 67(3):616-25. PubMed ID: 25470338
[TBL] [Abstract][Full Text] [Related]
8. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Cohen S; Radominski SC; Gomez-Reino JJ; Wang L; Krishnaswami S; Wood SP; Soma K; Nduaka CI; Kwok K; Valdez H; Benda B; Riese R
Arthritis Rheumatol; 2014 Nov; 66(11):2924-37. PubMed ID: 25047021
[TBL] [Abstract][Full Text] [Related]
9. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
Winthrop KL; Curtis JR; Lindsey S; Tanaka Y; Yamaoka K; Valdez H; Hirose T; Nduaka CI; Wang L; Mendelsohn AM; Fan H; Chen C; Bananis E
Arthritis Rheumatol; 2017 Oct; 69(10):1960-1968. PubMed ID: 28845604
[TBL] [Abstract][Full Text] [Related]
10. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.
Schulze-Koops H; Strand V; Nduaka C; DeMasi R; Wallenstein G; Kwok K; Wang L
Rheumatology (Oxford); 2017 Jan; 56(1):46-57. PubMed ID: 28028154
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
Sands BE; Taub PR; Armuzzi A; Friedman GS; Moscariello M; Lawendy N; Pedersen RD; Chan G; Nduaka CI; Quirk D; Salese L; Su C; Feagan BG
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):123-132.e3. PubMed ID: 31077827
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
Curtis JR; Schulze-Koops H; Takiya L; Mebus CA; Terry KK; Biswas P; Jones TV
Clin Exp Rheumatol; 2017; 35(3):390-400. PubMed ID: 28079500
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Wollenhaupt J; Lee EB; Curtis JR; Silverfield J; Terry K; Soma K; Mojcik C; DeMasi R; Strengholt S; Kwok K; Lazariciu I; Wang L; Cohen S
Arthritis Res Ther; 2019 Apr; 21(1):89. PubMed ID: 30953540
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
17. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.
Buch MH; Bhatt DL; Charles-Schoeman C; Giles JT; Mikuls T; Koch GG; Ytterberg S; Nagy E; Jo H; Kwok K; Connell CA; Masri KR; Yndestad A
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38609322
[TBL] [Abstract][Full Text] [Related]
18. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis.
Souto A; Salgado E; Maneiro JR; Mera A; Carmona L; Gómez-Reino JJ
Arthritis Rheumatol; 2015 Jan; 67(1):117-27. PubMed ID: 25303044
[TBL] [Abstract][Full Text] [Related]
19. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration.
Navarro-Millán I; Yang S; DuVall SL; Chen L; Baddley J; Cannon GW; Delzell ES; Zhang J; Safford MM; Patkar NM; Mikuls TR; Singh JA; Curtis JR
Ann Rheum Dis; 2016 Feb; 75(2):341-7. PubMed ID: 25609412
[TBL] [Abstract][Full Text] [Related]
20. Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Curtis JR; Zhang R; Krishnaswami S; Anisfeld A; Chen Y; Strengholt S; Chen C; Geier J
Clin Rheumatol; 2017 Mar; 36(3):683-688. PubMed ID: 27470086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]